Gabapentin (All indications)

Oro-facial clefts

R analysis
id Study   Lib. in paper Exposition period    Study type 
 Control type 
 
Tags OR 95%CI x1/n1 x0/n0 no cases no exposed ROB Ref.
S15270
R62758		 Desrochers, 2022 Orofacial malformations 1st trimester retrospective cohort (claims database) unexposed (general population or NOS) Adjustment: Yes 1.37 [0.50;3.77] -/-   -/288,357 - -
ref
S10033
R46485		 Blotière (Controls exposed to Lamotrigine, sick) (Other indications), 2019 Oro-facial clefts 1st trimester retrospective cohort (claims database) exposed to other treatment, sick excluded Adjustment: No 0.91 [0.05;16.98] C
excluded (control group) 		0/365   4/2,997 4 365
ref
S10034
R46486		 Blotière (Controls unexposed NOS) (Other indications), 2019 Oro-facial clefts 1st trimester retrospective cohort (claims database) unexposed (general population or NOS) Adjustment: No 0.91 [0.06;14.62] C 0/365   2,815/1,875,733 2,815 365
ref
S8493
R27899		 Morrow (Controls exposed to Lamotrigine, sick), 2006 Facial cleft 1st trimester prospective cohort exposed to other treatment, sick Adjustment: No 7.05 [0.28;176.78] C 0/31   1/647 1 31
ref
Total 3 studies 1.49 [0.60;3.72] 2,816 396
x1: number of endpoints among exposed, n1: number of exposed; x0: number of endpoints among non exposed, n0: number of non exposed; C: calculated odds ratio from numbers of events and effectives

Forest plot

StudyTE95% CIn casesn exposedweightROBABCDEF Desrochers, 2022Desrochers, 2022 1.37[0.50; 3.77]--81%ROB confusion: unclearROB selection: unclearROB classification: unclearROB missing: unclearROB mesure: unclearROB reporting: moderate Blotière (Controls unexposed NOS) (Other indications), 2019Blotière, 2019 1 0.91[0.06; 14.62]2,81536511%ROB confusion: NAROB selection: NAROB classification: NAROB missing: NAROB mesure: NAROB reporting: NA Morrow (Controls exposed to Lamotrigine, sick), 2006Morrow, 2006 2 7.05[0.28; 176.78]1318%ROB confusion: NAROB selection: NAROB classification: NAROB missing: NAROB mesure: NAROB reporting: NA Total (3 studies) I2 = 0% 1.49[0.60; 3.72]2,8163960.220.01.0ROB: A: confusion, B: selection, C: classification, D: missing, E: measurement, F: reportinglow,moderate,serious,critical,unclear,

1: Controls unexposed NOS) (Other indications; 2: Controls exposed to Lamotrigine, sick;

Sensitivity analysis

SubsetTE95% CIn casesn exposedkI2 Type of studies cohort studiescohort studies 1.49[0.60; 3.72]2,8163960%NADesrochers, 2022 Blotière (Controls unexposed NOS) (Other indications), 2019 Morrow (Controls exposed to Lamotrigine, sick), 2006 3 case control studiescase control studies 0 Type of controls unexposed (disease free or unspecified)unexposed (disease free or unspecified) 1.31[0.51; 3.37]2,8153650%NADesrochers, 2022 Blotière (Controls unexposed NOS) (Other indications), 2019 2 exposed to other treatment, sickexposed to other treatment, sick 7.05[0.28; 176.78]131 -NAMorrow (Controls exposed to Lamotrigine, sick), 2006 1 Tags Adjustment   - No  - No 2.18[0.27; 17.84]2,8163960%NABlotière (Controls unexposed NOS) (Other indications), 2019 Morrow (Controls exposed to Lamotrigine, sick), 2006 2   - Yes  - Yes 1.37[0.50; 3.76]-- -NADesrochers, 2022 1 All studiesAll studies 1.49[0.60; 3.72]2,8163960%NADesrochers, 2022 Blotière (Controls unexposed NOS) (Other indications), 2019 Morrow (Controls exposed to Lamotrigine, sick), 2006 30.220.01.0

Publication bias and p-hacking diagnosis

funnel plot

Funnel plot not drawn. Less than 3 points.

Asymetry test p-value = NaN (by Egger's regression)

not enought points

p values plot

Funnel plot not drawn. Less than 3 points.

Sub-groups analysis using all included studies

excluded 10033

Sub-groupsTE95% CIn casesn exposedkI2ROB type of controls unexposed controls (disease free or unspecified)unexposed controls (disease free or unspecified) 1.31[0.51; 3.37]2,8153650%NADesrochers, 2022 Blotière (Controls unexposed NOS) (Other indications), 2019 2 exposed to other treatment, sick controlsexposed to other treatment, sick controls 2.30[0.26; 20.03]53960%NABlotière (Controls exposed to Lamotrigine, sick) (Other indications), 2019 Morrow (Controls exposed to Lamotrigine, sick), 2006 20.510.01.0